# **Special Issue**

# Advances in Pharmacokinetics of Targeted Anti-Cancer Drugs

## Message from the Guest Editors

The ever-evolving field of targeted cancer therapies has significantly reshaped cancer treatment paradigms, offering greater precision and efficacy compared to traditional chemotherapy. Central to this revolution is the advancement of pharmacokinetics (PK) of targeted anti-cancer drugs, which plays a crucial role in optimizing drug delivery, efficacy, and safety profiles. Recent developments in PK studies have provided valuable insights into the absorption, distribution, metabolism, and excretion (ADME) properties of novel targeted agents, thereby informing their clinical use.

Recent innovations in drug delivery systems, such as nanotechnology and antibody–drug conjugates (ADCs), have further advanced PK strategies by enhancing drug specificity and minimizing systemic toxicity. As the field progresses, continued research into the pharmacokinetics of targeted anti-cancer therapies is essential for refining these treatments and improving patient outcomes across diverse cancer types.

Articles reflecting this ethos are welcome for the special edition.

## **Guest Editors**

Dr. Marios Spanakis

- 1. Department of Forensic Sciences and Toxicology, Faculty of Medicine, University of Crete, Heraklion, Greece
- 2. Computational BioMedicine Lab, Institute of Computer Science, Foundation for Research & Technology—Hellas, Heraklion, Greece

### Dr. Retheesh S. Thankan

Department of Pharmacology, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA

## Deadline for manuscript submissions

20 January 2026



## **Pharmaceutics**

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/242924

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

#### Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

## **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

## **Journal Rank:**

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

